Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Cash from Financing Activities data on file, last reported at -$272.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 71.03% year-over-year to -$272.7 million; the trailing twelve-month figure through Mar 2026 stood at -$517.3 million (down 40.52% YoY), and the FY2025 full-year result was -$1.2 billion, down 428.39% from the prior year.
• Cash from Financing Activities rose to -$272.7 million in Q1 2026, from -$299.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.2 billion in Q2 2024 to a low of -$1.4 billion in Q3 2023.
• A 5-year average of -$246.5 million and a median of -$258.0 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 490.86% in 2023 and surged 433.32% in 2024, its largest moves.
• Tracing RPRX's Cash from Financing Activities over 5 years: stood at -$265.6 million in 2022, then climbed by 12.67% to -$231.9 million in 2023, then declined by 11.24% to -$258.0 million in 2024, then slipped by 16.14% to -$299.6 million in 2025, then climbed by 8.99% to -$272.7 million in 2026.
• Business Quant data shows RPRX's Cash from Financing Activities at -$272.7 million in Q1 2026, -$299.6 million in Q4 2025, and $562.7 million in Q3 2025.